SLNO · As filed with the SEC
Soleno Therapeutics balance sheet, by quarter
The statement as Soleno Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets · USD
| USD | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | 133,026,000 | 70,106,000 | 246,662,000 | 76,497,000 | 81,331,000 | 87,928,000 | 48,413,000 | 57,024,000 |
| Marketable securities | 122,573,000 | 235,366,000 | 252,272,000 | 210,344,000 | 208,619,000 | 203,509,000 | 208,363,000 | 209,099,000 |
| Accounts receivable, net | 47,139,000 | 28,208,000 | 25,506,000 | 24,624,000 | — | — | — | — |
| Inventory, net | 17,308,000 | 15,024,000 | 6,674,000 | 2,355,000 | — | — | — | — |
| Prepaid expenses and other current assets | 6,330,000 | 7,110,000 | 3,739,000 | 2,969,000 | 18,965,000 | 2,452,000 | 1,423,000 | 1,379,000 |
| Total current assets | 326,376,000 | 355,814,000 | 534,853,000 | 316,789,000 | 308,915,000 | 293,889,000 | 258,199,000 | 267,502,000 |
| Long-term assets | ||||||||
| Property and equipment, net | 202,000 | 185,000 | 150,000 | 166,000 | 173,000 | 186,000 | 196,000 | 19,000 |
| Operating lease right-of-use assets | 3,891,000 | 2,191,000 | 2,314,000 | 2,434,000 | 2,603,000 | 2,798,000 | 2,992,000 | 268,000 |
| Intangible assets, net | 4,374,000 | 4,861,000 | 5,347,000 | 5,832,000 | 6,318,000 | 6,805,000 | 7,291,000 | 7,777,000 |
| Long-term marketable securities | 273,382,000 | 200,616,000 | 57,148,000 | 7,002,000 | 0 | 27,211,000 | 27,945,000 | 28,482,000 |
| Other long-term assets | 163,000 | 163,000 | 83,000 | 83,000 | 83,000 | 83,000 | 83,000 | 83,000 |
| Total assets | 608,388,000 | 563,830,000 | 599,895,000 | 332,306,000 | 318,092,000 | 330,972,000 | 296,706,000 | 304,131,000 |
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | 12,386,000 | 12,435,000 | 8,145,000 | 6,216,000 | 5,483,000 | 8,882,000 | 6,243,000 | 3,716,000 |
| Accrued compensation | 5,723,000 | 9,677,000 | 7,248,000 | 6,267,000 | 4,277,000 | 4,776,000 | 3,408,000 | 2,149,000 |
| Accrued clinical trial site costs | — | — | — | 1,863,000 | 1,824,000 | 1,826,000 | 1,762,000 | 1,863,000 |
| Operating lease liabilities | 1,163,000 | 726,000 | 697,000 | 676,000 | 597,000 | 526,000 | 448,000 | 296,000 |
| Accrued interest payable | — | — | — | 409,000 | 423,000 | — | — | — |
| Contingent liability for Essentialis purchase price | 13,846,000 | 20,327,000 | — | — | — | — | — | — |
| Other current liabilities | 24,931,000 | 18,198,000 | 17,163,000 | 5,512,000 | 3,127,000 | 2,737,000 | 3,101,000 | 1,126,000 |
| Total current liabilities | 58,049,000 | 61,363,000 | 33,253,000 | 20,943,000 | 15,731,000 | 18,747,000 | 14,962,000 | 9,150,000 |
| Long-term liabilities | ||||||||
| Contingent liability for Essentialis purchase price | — | — | 19,473,000 | 18,859,000 | 17,758,000 | 14,791,000 | 14,464,000 | 13,587,000 |
| Common stock purchase liability | — | — | — | — | — | — | — | 637,000 |
| Long-term debt, net | 49,871,000 | 49,863,000 | 49,854,000 | 49,845,000 | 49,836,000 | 49,828,000 | — | — |
| Long-term lease liabilities | 3,243,000 | 1,964,000 | 2,112,000 | 2,248,000 | 2,361,000 | 2,472,000 | 2,581,000 | 0 |
| Other long-term liabilities | 1,425,000 | 525,000 | 398,000 | 271,000 | 145,000 | 21,000 | — | — |
| Total liabilities | 112,588,000 | 113,715,000 | 105,090,000 | 92,166,000 | 85,831,000 | 85,859,000 | 32,007,000 | 23,374,000 |
| Stockholders’ equity | ||||||||
| Common stock, $0.001 par value, 100,000,000 shares authorized, 51,718,149 and 52,286,881 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 52,000 | 52,000 | 54,000 | 50,000 | 49,000 | 46,000 | 41,000 | 38,000 |
| Additional paid-in-capital | 897,578,000 | 881,018,000 | 969,119,000 | 740,746,000 | 728,019,000 | 696,966,000 | 660,041,000 | 600,534,000 |
| Accumulated other comprehensive income (loss) | (1,838,000) | 415,000 | 360,000 | 85,000 | 226,000 | 361,000 | 895,000 | (153,000) |
| Accumulated deficit | (399,992,000) | (431,370,000) | (474,728,000) | (500,741,000) | (496,033,000) | (452,260,000) | (396,278,000) | (319,662,000) |
| Total stockholders’ equity | 495,800,000 | 450,115,000 | 494,805,000 | 240,140,000 | 232,261,000 | 245,113,000 | 264,699,000 | 280,757,000 |
| Total liabilities and stockholders’ equity | 608,388,000 | 563,830,000 | 599,895,000 | 332,306,000 | 318,092,000 | 330,972,000 | 296,706,000 | 304,131,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.